Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.3
Journals
JCM
Special Issues
Most Advanced Therapeutic Agents Redefining Neurological Health
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Most Advanced Therapeutic Agents Redefining Neurological Health

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".

Deadline for manuscript submissions: closed (15 April 2026) | Viewed by 796

Editor

Dr. Clarissa Fantin Cavarsan

E-Mail Website
Guest Editor
Neuroscience and Behavior Program, Wesleyan University, Middletown, CT 06459, USA
Interests: neurodegeneration; neuroimmunomodulation; neuroscience and behavior
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent clinical trials have established several novel therapeutics as practice-changing interventions in neurology. Regarding the treatment of Alzheimer's disease, anti-amyloid monoclonal antibodies (lecanemab, donanemab) now demonstrate the statistically significant slowing of cognitive decline (CDR-SB 27–35%) in phase 3 trials when initiated at early disease stages. Parkinson's therapeutics now include targeted agents like safinamide (MAO-B/glutamate modulation), showing improved motor fluctuations in extension studies, while subcutaneous apomorphine infusion provides effective rescue therapy. In MS, CD20-depleting therapies (ocrelizumab, ofatumumab) achieve 85–90% relapse reduction with manageable infection risks. Acute neuroprotection is now achievable with tenecteplase (0.4 mg/kg) for large-vessel occlusion strokes, showing superior reperfusion to alteplase in recent RCTs. For SMA, onasemnogene abeparvovec produces 90% survival without ventilation at 24 months when administered presymptomatically. These advances mandate updated treatment algorithms, emphasizing (1) earlier biomarker-guided intervention, (2) combination approaches, and (3) rigorous monitoring for ARIA (amyloid therapies) and IRIS (immune reconstitution) effects.

Dr. Clarissa Fantin Cavarsan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • disease-modifying therapy
  • biomarker-guided treatment
  • gene therapy
  • neuroprotection
  • clinical trials
  • neurological disorders
  • precision neurology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

15 pages, 1569 KB  
Systematic Review
Alternative Treatment of the Resistant-to-Treatment Tourette Syndrome—A Systematic Review
by Agata Czech, Magdalena Czarnecka, Olga Grodzka, Piotr Chądzyński and Izabela Domitrz
J. Clin. Med. 2026, 15(9), 3393; https://doi.org/10.3390/jcm15093393 - 29 Apr 2026
Viewed by 530
Abstract
Background: Tourette syndrome (TS) is a chronic neurodevelopmental disorder with a significant rate of patients remaining refractory to standard treatments. Refractory TS is defined as the persistence of clinically significant tics causing functional impairment despite adequate trials of both behavioral therapy and at [...] Read more.
Background: Tourette syndrome (TS) is a chronic neurodevelopmental disorder with a significant rate of patients remaining refractory to standard treatments. Refractory TS is defined as the persistence of clinically significant tics causing functional impairment despite adequate trials of both behavioral therapy and at least two generally accepted pharmacological treatments from different classes, administered at appropriate doses and durations. This systematic review synthesizes the current evidence on alternative pharmacological and non-pharmacological interventions for treatment-resistant TS. Methods: The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. PubMed, Embase, and Scopus were searched for studies published from 2010 onward. Eligible publications included randomized and non-randomized clinical studies, and case reports evaluating alternative interventions in refractory TS, excluding deep brain stimulation. The primary outcome measures included validated scales assessing tic severity and functional impairment, with available data demonstrating reductions in tic severity, including clinically meaningful improvements reported in several studies. Thirteen studies met the inclusion criteria, comprising five clinical studies (including three randomized trials) and eight case reports. Heterogeneity across studies was primarily driven by differences in study design, patient populations, and variability in intervention types, protocols, and outcome assessments. Results: Investigated interventions included cannabinoids, valproic acid, deep transcranial magnetic stimulation, neurofeedback, biofeedback, electroconvulsive therapy, and ablative neurosurgical procedures. Cannabinoid-based treatments showed potential reductions in tic severity; however, results were inconsistent and often not statistically significant, with evidence largely derived from small or uncontrolled studies. Evidence for non-pharmacological approaches was limited and largely derived from individual cases, with some modalities showing potential benefit in specific subgroups, such as patients with comorbid obsessive-compulsive disorder. Conclusions: Overall, alternative interventions may offer therapeutic value for selected individuals with treatment-resistant TS, with the greatest data regarding cannabinoid use; however, the current evidence base remains heterogeneous and methodologically constrained. Deep transcranial magnetic stimulation might be beneficial in a specific patient population. Larger, well-controlled studies are required to clarify efficacy, safety, and treatment response. Full article
(This article belongs to the Special Issue Most Advanced Therapeutic Agents Redefining Neurological Health)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop